European stock markets remain mixed while Wall Street futures predict a negative start. Investor morale in the eurozone is improving, but with Germany in recession the hope of a spring recovery is still uncertain
U.S. Food and Drug Administration 510(k) clearance obtained in advance. DiaSorin thus strengthens its position in the syndromic multiplexing market. The stock shines on Piazza Affari, +4%
Uncertainty about the timing of rate cuts in both America and Europe is weighing on the markets. Diasorin, Recordati, Unipol, Hera and A2A are the most popular stocks on Piazza Affari
After a fight at the last exchange, Leonardo wins the scepter of the best Ftse Mib stock with an increase of more than 85% - Record performance for the banks, Stellantis in third place - Here is the ranking of the best and…
Europe is heartened by lower-than-expected inflation and the hope of an end to the rate increase. Spreads decreasing, tension on BTPs decreases. Diasorin and Prysmian stand out in Milan
Revenues amount to 290 million euros. The reduction in margins is mainly a consequence of the lower Covid revenues. Guidance 2023 confirmed
Sales of anti-Covid tests decreased by 35% compared to 2021, but in 2022 overall revenues rise by 10% - 2023 is expected to reduce revenue by 14%
In view of the rate hike by the Fed today and by the ECB tomorrow, the decoupling of the stock exchanges starts: Europe slows down, Wall Street accelerates - Slight increase in the Btp-Bund spread
Piazza Affari closes slightly higher thanks to purchases of pharma stocks and Tim who moves at the pace of rumors about the future of the network - Oil redeems itself, gas volatile
The Piedmontese diagnostic company has announced the commercialization of the pair of primers that will be used both to validate molecular tests for diagnostic purposes and for research
General rebound on the stock markets with Milan on the rise thanks to Pharma and Utility - The pressure on the Btp is decreasing - US banks' two-speed quarterly reports
Stock market session with high volatility with continuous reversals - Piazza Affari, like Paris and Frankfurt, however, also closed higher
In the first half Diasorin recorded a profit above consensus and a double-digit leap in revenues and turnover. And he sees the guidance for the end of 2022 rising
Thanks to the acquisition of Luminex, Diasorin closed the 2021 financial year with profits up 25% and revenues up 40,4% - Title promoted to "buy" by Equita and Banca Akros
This is the new version of an already used test and does not serve for diagnostic purposes - It can be performed directly on samples collected by swab
On the day of the technical deadlines (the 4 witches) the markets reduce the initial losses in the final but volatility remains high - Piazza Affari loses 0,6% and rejects the new Diasorin plan which leaves almost 11% in the field
Ex-Covid turnover is expected to grow by 24% in 2022, total turnover down by 2% - Covid revenues down from 370 million in 2021 to 150 million in 2022 - New programs in immunodiagnostics kick off
The accommodative monetary policy of the ECB pushes the stock markets of Southern Europe while Wall Street sparks despite the slowdown in US GDP
The acquisition of the American company, costing 1,2 billion, will create a group with a turnover of 1,25 billion euros and an adjusted EBITDA of 472 million
After Draghi's words, Ankara freezes a million-dollar contract with the Italian group - Diasorin buys the American Luminex - Powell (Fed): "US economy strong, it's not time to raise rates" - Record fine for Alibaba in China , but…
The Ftse Mib index is slowly approaching the psychological threshold of 25 basis points - Recordati, Diasorin, Amplifon and Leonardi are the best stocks of today's session.
Piazza Affari slows down the pace, as well as the other European squares, after the rush of the last few days. Weak banks, but above all utilities and construction. The spread remains below 100 basis points, oil rises.
The delays in anti-Covid vaccinations and the winds of bubbles arriving from Wall Street are causing anxiety to the stock exchanges which are waiting for signs from Powell's Fed - Piazza Affari loses 1,5%: Interpump collapses, Stellantis does badly, Diasorin goes against the trend...
For the stock exchanges, 2020 was a complicated and difficult year, but if a few months ago they had told us that it would end like this, that is, with very limited losses - -5,4% for Piazza Affari - compared to the monstrosity of Covid or…
Piazza Affari, in line with the other Stock Exchanges, closed the last session of a year in which the Ftse Mib lost just over 5% slightly lower.
For months, investors have been participating in the search for the Holy Grail, or the vaccine capable of defeating Covid - Big Pharma stocks engaged in the roller coaster ride between hopes and cold showers
At the end of the morning, European lists lose more than 2% - Only Diasorin is saved in Piazza Affari - Strong sales on CNH and on banks
All the stock markets are up and in Piazza Affari Stm and Diasorin are leading the relaunch - Sparks on the Nasdaq which gains more than 2,5% after the first two hours of the session - Bots ok with rates at their lowest since February.
After the surges of recent days linked to the Recovery Fund and risk, bank stocks suffer and the Ftse Mib is affected - Strong sales also on Atlantia and Diasorin
Gold and silver continue to set records - The stock markets are down on the other hand and the judicial vicissitudes of Eni CEO Descalzi and Diasorin are also weighing on Milan.
Stock falls in the middle of the day after the news of the investigation by the Pavia prosecutor's office on the agreement between the company and the San Matteo polyclinic on serological and molecular tests - CEO Carlo Rosa among the suspects
Leonardo Del Vecchio's Mediobanca takeover project excites the Stock Exchange and the share of the Milanese merchant bank gains over 8% - Generali, Cnh, Leonardo and Banco Bpm also do well - Cattolica Assicurazioni pays the capital increase
May ends in decline for all stock lists, tormented by the thousand uncertainties that dominate the international economic and financial scene - The rebounds of Diasorin and Nexi however help Piazza Affari to limit the damage - Enel does well too…
The EU's move initially invigorates Piazza Affari which then resets its earnings - Unicredit, Intesa, Mediobanca, Pirelli and CNH shine - Diasorin is very bad, which loses more than 12% due to profits, while Nexi pays for the divestment of…
European stock markets worsen in the middle of the day after the words of the Fed president and the data of the European Bank which indicate uncertainty about the recovery
The shares of the Italian pharma have achieved a progress of 90% in one year. Good quarterly report and prospects - Canada adopts serological testing. And in Lodi a Chinese competitor appears "masked" as an Italian
London suffers, Milan positive - Spreads up - Oil down despite the announcement of the cuts - Gold on the rise - Generali advances in Piazza Affari, banks down.
The postponement of the Eurogroup to Thursday brings sales back but the ECB in the field supports the European lists. Diasorin's race continues - Oil recovers pending OPEC meeting
Failure to reach an agreement in the Eurogroup, reconvened for tomorrow morning, cools the stock exchanges - Wall Street starts strong and ends up in decline - Sparks from the Agnelli team in Piazza Affari - Atlantia deflates - Oil restarts
After a moderate start, the Milan Stock Exchange retraces and closes in strong red (-3,2%) - All stock markets are negative, Wall Street volatile - Banca Mediolanum and Atlantia sink in Piazza Affari - Diasorin leaps up for …
After Monday's storm, the push for purchases starts from Asia - Eni and Leonardo rise again, Intesa leads the banks. Oil on the swing. Waiting for Wall Street
Time to diagnosis reduced from 5-7 hours to 60 minutes - Company announces completion of studies needed to gain approval in EU and US
The US company Thermo Fischer has offered 10,4 billion euros for Qiagen, a German company that has an agreement with Diasorin - Sector headlines are racing
The improbability of an agreement in extremis between Europe and the United Kingdom shakes the stock exchanges, also tormented by the uncertainty on the US-China negotiations on duties - All share lists are in the red, including Piazza Affari: Diasorin and Fineco collapse - Okay…
The group led by Carlo Rosa has signed an agreement with Beckman Coulter Diagnostics to supply the Liaison XL tests for hepatitis A, B and C, as well as for HIV testing, in the United States.
The Italian company has signed a $2,6 million contract with the US Department of Health to "develop a fully automated solution capable of detecting Zika infections in the laboratory"
Not everyone weeps on the day when Piazza Affari loses 2,35 and turns out to be the worst Stock Exchange in Europe: more than a dozen stocks fly and even mid-cap stocks like Diasorin go against the tide, making a leap…
The dividend will rise to 0,55 euro per share, from 0,50 in 2012 - Net revenues rose by 0,3%, to 432,8 million, while Ebitda fell by 3,8%, to 163,1 million - Net income also decreased (-5,2%), due to…
In the four years since its debut, in December 2009, Yoox has managed to multiply its value by more than seven times compared to the price that had been set during the placement phase (from 4,3 to over 31 euros), consequently…
For 5 years, laboratories all over the world will be able to take advantage of an integrated and automated system that will allow better productivity and greater savings.
In green and against the trend Diasorin which recorded an increase of 1,48% to 32,24 euros which represents the only recovery of the Ftse Mib - Tenaris also made a comeback after 11 am.
It was the CEO of the company, Carlo Rosa, who anticipated the news during the presentation of the results for the second quarter - The company recorded a +1,7% on the Stock Exchange, even if the accounts were slightly lower than the expectations of the …
Weak session for the European stock exchanges, including Piazza Affari - All eyes are on the top of the Fed: at 20 (Italian time) the president Ben Bernanke will hold a press conference on the monetary stimulus plan, eagerly awaited for days -…
The company closed the period with a profit of 20,5 million (22,5 million in the first quarter of 2012), an Ebitda of 41,6 million and revenues of 105,8 million (105,7 million a year earlier). - The company has confirmed…
2012 for the diagnostics company ended with declining profits and turnover, but the Board of Directors proposes an increase in dividends compared to the previous year, from 0,46 to 0,50 euros per share - the stock is bad on the Stock Exchange.
The Italian Stock Exchange closes a week plagued by electoral effects in the red: -1,5% - The danger of the US kidnapper (public spending cuts) weighs on European lists - Mediaset collapses (-6,6%) after the request by the Public Prosecutor's Milan to condemn…
Under the terms of the agreement, the DiaSorin Group and the Trivitron Group have set up DiaSorin Trivitron Healthcare Private Limited, a limited liability company based in Chennai, in which the parties own 51% and 49% respectively and which will operate directly…
After a worrying start, the Milan Stock Exchange, driven by banks and industry, recovers ground and is the best list in Europe - Exploit by TiMMedia (+22%) for the assumptions of the sale of assets (but not La7), by Bpm and mps…
The Milan Stock Exchange, after a downward start, reversed the trend and, in the middle of the day, gained 0,6% resulting in the best price list in Europe - Spread below 390 and the euro recovering - Bpm and Diasorino stand out - Starting again…
The group has received authorization to market in the United States a new immunoassay developed for the quantitative determination of vitamin D levels.
Schauble admits that a final decision on the debt crisis in the Eurozone will not be reached at the European summit on 23 October - Even Merkel puts her hands forward - And so the European lists sink and the opening in the red…
The world's leading molecular diagnostics company sees its turnover grow by 20% every year. At the end of the next four years it is expected to be close to 700 million, thanks to the conquest of new markets such as India and Japan. But analysts…
